INTRODUCTION
Lgl is a tumour suppressor first identified in Drosophila that has important roles in regulating cell polarity, establishing an epithelial phenotype and orchestrating asymmetrical cell division in stem cells such as neuroblasts. [1] [2] [3] [4] Two homologues of the Lgl Drosophila gene are present in all species so far studied; loss of which is associated with disruption of cell polarity and epithelial architecture and uncontrolled proliferation. [5] [6] [7] In humans, reduced expression of Hugl-1 (LLGL1, Lgl1, mLGL1, DLG4) and Hugl-2 (LLGL2, HGL, mLgl2, LGL2) is implicated in the progression of a number of human tumours, including prostrate, melanoma, ovarian, colon, gastric and endometrial cancer. [8] [9] [10] [11] [12] [13] Recently, aberrant splicing of Hugl-1 was detected in hepatocellular carcinoma and expression of a particular variant was associated with tumour progression and poor prognosis adding a new aspect to Lgl tumour biology.
14 Consistent with its function in maintaining an epithelial phenotype is the recent data in which Hugl-2 may be useful as a biomarker for distinguishing low-grade pancreatic tumours with Hugl-2 expression from higher grade tumours and adenocarcinomas, which show loss or aberrant localization of Hugl-2. 15 Indeed, it was shown that well-differentiated pre-cancer lesions with K-Ras mutations and Ras dependency maintain an epithelial expression signature including Hugl-2. 16 Furthermore, an ever increasing number of studies fingerprinting tumour collectives using gene array technologies or comparative genomic hybridizations have linked Hugl-1 and Hugl-2 to signatures predicting disease severity. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Together, these data argue preventing the loss of or re-establishing Hugl-2 expression in tumours should have positive outcomes for cancer patients.
Disruption of polarity in epithelial cells is considered one of the changes on the path to aggressive cancer. The reversible transition of cells between different polarity states are essential programs during mammalian development and in certain physiological settings such as wound healing. Current paradigms consider that these transitions may be inappropriately reinitiated during tumour progression endowing cells with malignant properties. [32] [33] [34] For example, epithelial cells switching to more mesenchymal-like cancer cells, termed epithelial-mesenchymal transition (EMT) switch from apico-basal polarized, epithelial phenotype to a more fibroblastoid or mesenchymal phenotype characterized by reduced cell-cell adhesion, attenuated apicobasal polarity and increased migratory cell-type polarity with enhanced invasive properties. A number of studies suggest a wider role for EMT programs in tumour progression as has been previously thought; for example, by modulating pathways that are involved in resistance to apoptosis and chemotherapeutics as well as inducing cytokine expression. [34] [35] [36] [37] The reverse of EMT, or the change in polarity from migratory cell-type to epitheliod-type cell or so-called mesenchymal-to-epithelial transitions (MET) is not as well studied in the context of cancer, but has been suggested to occur at a stage of metastasis when nesting of migrating tumour cells at a secondary tumour site is enhanced by more adhesive epithelial-like properties. Thus, in the context of tumour biology, the programs affecting cellular plasticity have emerged as candidate targets for cancer therapy.
A large set of data has accumulated that the molecular and cellular mechanisms governing these programs are coordinated through transcription factors including Snail, Twist, Slug (Snail2) and ZEB, which induce changes in gene expression leading to loss of epithelial traits and the acquisition of mesenchymal phenotype. [38] [39] [40] [41] Although E-cadherin is the most widely studied target downregulated by EMTinducing transcription factors, additional targets governing, for example, apoptosis sensitivity and cell cycle regulation support the idea that the changes encompassing EMT represent a broader malignant phenotype. 34, 41 Recently, polarity proteins were shown regulated by EMT-inducing transcription factors, underscoring the link to tumour progression and polarity loss. [42] [43] [44] Here, we investigated the regulation of Hugl-1 and Hugl-2 by EMT inducers using E-cadherin as reference. We found that the Hugl-2 promoter responds to Snail and Zeb-1, less to Slug and is essentially unresponsive to Twist, whereas Hugl-1 did not respond significantly to any of these EMT inducers. This was in contrast to E-cadherin that showed significant repression to all EMT inducers. Further characterization of Hugl-2 and Snail interaction showed that Snail binds two paired E-boxes in the promoter region of Hugl-2 for mediating the repression. Using ecdysone-inducibleHugl-2 cells expressing constitutive Snail and breast cancer cells, we could show MET induction by Hugl-2 in Snail cells and downregulation of Snail in the nucleus as well as a reduction of in vivo tumour growth, or in the case of breast cancer cells, their dissemination in mice. Together, our results place Hugl-2 as a target of a subset of transcription factors, which have been implicated in tumour progression. [44] [45] [46] [47] The reversal of the tumoral phenotype by re-expression of Hugl-2 suggests that inducing MET may be a promising cancer therapy strategy.
RESULTS
Snail binds and represses Hugl-2, but not Hugl-1 We investigated EMT-transcription factors Snail, Slug, Twist and Zeb-1 as possible regulators of Hugl-1 and Hugl-2 by co-transfection assays of luciferase reporters. E-cadherin was used as control. Snail and Zeb-1 specifically represses the Hugl-2 promoter, whereas Slug and Twist had less effect in comparison with Hugl-1, which was unresponsive to all factors ( Figure 1a) . The inhibition by Snail of Hugl-2 was dose dependent in Hek293, HepG2 and Cos-7 cells in which 90, 72 and 86% inhibition was observed, respectively, at the maximum dose of Snail ( Figure 1a middle and Supplementary Figure S1 ). We examined the MDA-MB-231 breast cancer cell line, which expresses Snail endogenously. In MDA-MB-231 cells, the Hugl-2 promoter-luciferase construct showed reduced activity in comparison with Snailnegative MCF-7 breast cancer cells (Figure 1a , right). Closer examination of the Hugl-2 and Hugl-1 promoters revealed the presence in the Hugl-2 promoter of four sequences clustered in pairs with homology to E-box-binding sites described for the human E-cadherin gene (CACCTG) (Figure 1b) . 38 The Hugl-1 promoter sequence did not contain E-box sequences. For Hugl-2, we generated a series of reporter constructs carrying truncations of the promoter or mutations in each pair of E-boxes. Truncations of the promoter between positions À 300 and À 20 (DGC) reduced basal promoter activity dramatically, whereas this region alone (GC) had slightly increased basal promoter activity, suggesting this may represent the core of the promoter. Repression by Snail was observed in both of these constructs (Figure 1b) . Mutation of the distal E-boxes reduced the sensitivity to Snail repression, but reversion was more complete when either the proximal or both sets of E-boxes were mutated (Figure 1c) . We confirmed the interaction of Snail proteins directly to these putative binding sites by using electrophoretic mobility shift assays (EMSAs) (Figure 1d and Supplementary Figure S1b) . Recombinant Snail protein efficiently bound each of the proposed target sequences. The specificity of the retarded complex was demonstrated by competition with 200-fold excess of unlabelled wild-type or mutant oligonucleotides. Unlabelled wild-type oligonucleotides almost completely abolished formation of the complex, whereas the respective mutant oligonucleotides did not affect their formation. Supershift assays using nuclear extracts from hemagglutinin-tagged Snail protein (Snail-HA; HA, hemagglutinin) cells corroborated these results (Figure 1d, right) . Chromatin-immunoprecipitation (ChIP) assays demonstrated binding of Snail to the both E-box clusters in the native Hugl-2 promoter in vivo (Figure 1e ). Taken together, these results indicate that the proximal E-boxes in the core promoter are primarily responsible for repression of Hugl-2 by Snail.
Snail represses Hugl-2 expression We examined whether Snail inhibits Hugl-2 expression by generating Hek293 cells that ectopically express Snail-HA. These cells displayed changes in morphology from clustered epithelioidto-unclustered fibroblast-like cells typical for Snail-induced EMT (Figure 2a ). In addition, expression of Snail-HA increased the migratory behaviour of these cells (Figure 2b ). Snail overexpression resulted in reduced Hugl-2 mRNA and protein expression, which was also correlated with loss of the Snail-target genes E-cadherin and epithelial cytokeratin-18 (CK18) (Figure 2c , Supplementary Figure S1c) . Further, we observed an increase in mesenchymal Vimentin and MMP-9 ( Figure 2c ). Confocal laserscanning microscopy confirmed these results (Figure 2d ). We also investigated MDA-MB-231 cells for expression of Hugl-2 and E-cadherin after Snail knock-down by small interfering RNA. These experiments demonstrated that upon reducing endogenous Snail, both Hugl-2 and E-cadherin levels increased (Figure 2e ). Combined with our promoter studies, our results show that Hugl-2 is repressed at the transcriptional level by Snail leading to loss of Hugl-2 protein.
Hugl-2 expression promotes an epithelial programme Lgl proteins are important for establishing and maintaining cell polarity in a diversity of cell types and organisms. 6 Our finding that Hugl-2 is a target of Snail led us to investigate the possibility of reversing Snail-driven EMT through Hugl-2 expression. Thus, we asked whether Hugl-2 re-expression in Snail cells would suppress the mesenchymal phenotype. Using an ecdysone regulated system, we first established and characterized stable transfectants of Hek293 cells with an inducible Hugl-2 transgene (Figure 3a) . These cells showed localization of the inducible Hugl-2 to the cell cortex and regions of cell-cell contact similar to endogenously expressed Hugl-2 (see Figures 2d and 3d lower left image). We further examined whether the epithelial protein E-cadherin was influenced when Hugl-2 was expressed. E-cadherin promoter activity, transcripts and protein were increased after Hugl-2 induction suggesting regulation at the transcriptional level (Figures 3b and c) . E-cadherin increased dramatically and localized to the cellular cortex upon Hugl-2 induction (Figure 3d ) and extensively co-localized with Hugl-2 ( Figure 3d , right panel). To examine whether Hugl-2 displays tumour suppressor activity, immunodeficient mice were injected s.c. with cells expressing Hugl-2 or control cells. Hugl-2 suppressed tumour growth in animals injected with cells induced to express Hugl-2, whereas mice injected with control cells developed large tumours during a span of 30 days (Figure 3e ). These tumours were further analysed by immunofluorescence, which showed that induction of Hugl-2 expression not only enhances E-cadherin expression but also the expression of CK18 (Figure 3f ). Together these results suggest that Hugl-2 maintains an epithelial programme that opposes tumour growth.
Hugl-2 represses Snail-driven EMT Next, for studying whether Hugl-2 can suppress Snail-induced EMT, we ectopically expressed Snail-HA in Hek293-inducible-Hugl-2 cells. In the absence of Ponasterone A, these cells displayed an altered morphology similar to cells undergoing Snail-mediated EMT. However, after inducing Hugl-2 these cells became clustered and displayed a more pronounced epithelioid morphotype Hugl-2 suppresses Snail A Kashyap et al ( Figure 4a ). As our experiments were performed in cells ectopically expressing Snail, we were interested in investigating tumour cells expressing Snail endogenously. For these experiments we chose the MDA-MB-231 breast cancer cell line. In MDA-MB-231 cells, the Hugl-2 promoter-luciferase construct showed reduced activity in comparison with Snail-negative MCF-7 breast cancer cells ( Figure 1a ). Upon ectopic expression of Hugl-2 in MDA-MB-231 cells, morphological changes from spindle shaped to more clustered epithelioid like cells were observed ( Figure 4a , lower panels). We tested in a mixed culture wounding assay whether the migratory behaviour of Snail cells was affected by inducing Hugl-2. We observed large numbers of uninduced green cells (for example, expressing Snail but not Hugl-2) that migrated into the wound, whereas red labelled cells, for example, those expressing Hugl-2 remained in the unwounded or border areas ( Figure 4b ). We corroborated these results using unmixed, unlabelled cultures Hugl-2 suppresses Snail A Kashyap et al addition to altering the epithelial phenotype, Snail has been implicated in cell survival signalling. 36 In terms of cancer progression, acquisition of apoptosis resistance is often correlated with malignancy. Thus, we investigated whether apoptosis induced by CD95 stimulation was affected in cells with Snail and in Hugl-2-induced Snail cells. Snail expression reduced the apoptosis sensitivity, whereas Hugl-2 induction in these cells relieved the apoptosis suppression by Snail as shown by the increased apoptosis sensitivity. Further, in breast cancer cells with gain of Hugl-2, apoptosis sensitivity was increased (Figure 4i ). Our data suggest that Hugl-2 not only induces an epithelial differentiation programme by restoring the expression of E--cadherin and CK18, but also suppresses the pro-tumour effects of Snail by restoring apoptosis sensitivity. Hugl-2 expression modulates Snail activity by downregulating its nuclear localization The nuclear localization of Snail is a prerequisite for regulating its targets and thus EMT. Thus, we asked whether the nuclear localization of Snail may be affected by Hugl-2. In MDA-MB-231 or Hek293-Snail cells expressing Hugl-2, fractionation of the nuclei revealed reduced amounts of Snail were present (Figures 6a and  b) . Furthermore, the functional relevance of these findings could be shown through ChIP assays in which the Snail occupancy of the E-cadherin and Hugl-2 promoters was reduced in both Hek293-Snail and MDA-MB-231 cells expressing Hugl-2 compared with control transfected cells (Figure 6c) . Results of Hugl-2 and E-cadherin promoter reporter assays revealed increased promoter activity in Hugl-2-expressing cells, suggesting reduced activity of Snail in repressing these promoters consistent with the previous results (Figures 4h and 6c) . Examination by confocal laserscanning microscopy of MDA-MB-231 cells expressing Hugl-2 that were stained for Snail showed reduced nuclear localization of Snail in the presence of Hugl-2 (Figure 6d ). These results suggest that Hugl-2 suppresses Snail by reducing its nuclear localization and thus its binding to target promoters.
DISCUSSION
Here, we provide evidence that the polarity gene, Hugl-2, is a potential metastasis suppressor that is repressed by the Snail transcription factor and that expression of Hugl-2 in Snail-positive cells suppresses EMT by inducing MET. We demonstrate that Hugl-2 upregulates epithelial proteins, E-cadherin and CK18. In mouse xenografts, Hugl-2 acted as a tumour and metastasis suppressor in Hek293 grafts and prevented the dissemination of breast cancer cells. Interestingly, one of the actions of Hugl-2 to counter Snail EMT appears to involve decreasing nuclear localization of Snail leading to reduced promoter binding by Snail of its targets and thus a release of the repression at these promoters. Hugl-2 counteracts the pro-cancer effects induced by Snail, including apoptosis sensitivity, cellular motility and metastasis in vivo. Notably, the suppressor activities by Hugl-2 did not require lowering expression levels of Snail protein. By linking the polarity gene, Hugl-2, to a central EMT inducer such as Snail, we place Hugl-2 in a key cellular network whose role during tumorigenesis is well documented. Our data predict that aberrant Hugl-2 expression has consequences for both epithelial integrity and cancer progression. Furthermore, our data suggest therapies to re-establish expression of metastasis suppressors such as Hugl-2 may be promising. We analysed the response of both Hugl-1 and Hugl-2 promoters to a series of EMT-inducing transcription factors. As loss of Hugl-1 in tumours has been well documented by us and others; one of the objectives of this study was to determine if Hugl-1 might also be regulated by EMT-inducing transcription factors. Our results demonstrated a striking difference between Hugl-1 and Hugl-2. Hugl-1 is essentially unresponsive to these factors, whereas Hugl-2 was downregulated by a subset of these factors, Snail and Zeb-1. Previous studies also showed the responsiveness of Hugl-2 to Zeb-1 in colon cancer cells thus linking Hugl-2 directly to epithelial plasticity pathways. 42, 43 Although, all organisms studied to date, with exception of Drosophila, have two related Lgl genes, very little is known about their distinct or overlapping functions. 6 Developmental and tissue expression differences as well as divergent amino-acid sequences suggest specific functions. The expression of Hugl-1 is relatively high in brain which is consistent with the disrupted neuroepithelial phenotype of complete knockout mice for the mouse Mgl-1 (orthologue of Hugl-1). 48 Hugl-2 is intensely expressed in the liver but liver-specific knock-out mice for Mgl-2 display no overt phenotype during 1 year observation (our unpublished data). These results suggest complementary functions for Hugl-1 and Hugl-2 in most tissues although formally this has not been shown. It also raises the question as to whether a back up mechanism for ensuring epithelial integrity for complex Hugl-2 suppresses Snail A Kashyap et al organisms evolved by having two Lgl genes. Our results demonstrate one of the first distinguishing functional characteristics for Hugl-2 relative to Hugl-1 as target for the transcription factors involved in epithelial homoeostasis and supports the idea that its loss promotes tumour progression.
Interestingly, although E-cadherin, as expected, was repressed by all the EMT-transcription factors we tested, Hugl-2 was regulated by a subset of these factors. The significance of these results is not completely clear. The exact roles of these factors during tumorigenesis is just beginning to be unravelled, however, their interplay or the significance of their distinct target clusters is largely unknown. It is further not clear how E-boxes are differentially regulated in promoters, which contain them. A recent report supports the importance of EMT inducers targeting polarity genes such as Hugl-2. In this study, silencing of LOXL2, previously characterized as a regulator of Snail and E-cadherin, induced Hugl-2 while only modestly affecting E-cadherin levels in breast carcinoma cells. These studies underscore the contextspecific actions of EMT inducers such as LOXL2 in regulating subsets of targets in a particular carcinoma sub-type. Whereas the mechanisms are yet to be unravelled, a novel mode of action is postulated as a LOXL2 catalytic domain mutant showed similar repressive action of the Hugl-2 promoter. 49 Although, once thought to primarily affect in vitro cell motility and metastasis, EMT factors have a broader role in tumour progression by affecting processes involving cell death, senescence, resistance to chemotherapy, immune surveillance and inflammation. [34] [35] [36] [37] Thus, the suppression by Hugl-2 of Snail-induced apoptosis resistance as well as tumour growth and angiogenesis of tumours supports a role of Hugl-2 in counter-acting more than simply motility.
A conceptually attractive therapeutic strategy for targeting EMT pathways is to reverse EMT by inducing MET. Currently, both small molecules and interfering antibodies to receptors/ligands of growth factors or their downstream signalling pathways involved 
Hugl-2 suppresses Snail
A Kashyap et al in EMT are in clinical use or in Phase 1 trials. 34 Indeed, the resistance of some tumours to EGFR antagonists is correlated with expression of EMT markers, suggesting even a partial reversion of EMT would be useful in combination therapies. Consistent with this idea is the observation that E-cadherin-positive carcinomas responded better to treatment. 41 The majority of therapies presently available are aimed at reducing or partially inactivating molecules in a cancer-driving pathway. Much less attention has been paid to the development of therapeutics that activate tumour suppressor pathways although promising work with p53 validates this novel approach. 50, 51 We provide evidence that Hugl-2 can suppress Snail-induced EMT and metastasis in vivo as well as in vitro. Our results indicate that Hugl-2 counteracts Snail EMT by mechanisms, which do not directly target Snail expression but rather by inducing opposing functions. Thus, screening of small molecule libraries against tumour cells containing constructs of tumour suppressor promoters such as Hugl-2 linked with a reporter may be useful for identifying candidate MET agonists.
MATERIALS AND METHODS
Cell culture, transfection, reporter-gene assays and apoptosis analysis Cell lines were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Darmstadt, Germany) supplemented with 10% FCS, 1% L-glutamine, 1% penicillin-streptomycin and 1% HEPES (PAA, Coelbe, Germany). Cos-7, Hek293, MCF-7, MDA-MB-231 and HepG2 cells were transfected using transfectin (Biorad, Munich, Germany) according to manufacturer's instruction. Snail-expressing cells were prepared after transfection of Hek293 cells with pcDNA3-Snail-HA and selection with G418 (Invitrogen). Ecdysone-inducible-Hugl-2 cell clones were established after selecting G418 and Zeocin-(Invitrogen) resistant Hek293-EcR cells (Invitrogen) transfected with pIND-Hugl-2. Expression of Hugl-2 in these cells was analysed after induction with Ponasterone A (Invitrogen). The Ponasterone A concentrations used showed no overt side effects nor affected Erk signalling. Hek293-EcR-Snail/Hugl-2 (Hek293(Snail/Hugl-2 ind )) cell lines were established by transfecting pUB6-Snail-HA into Hek293-EcR Hugl-2 cells. Cells resistant for Zeocin, G418 and Blasticidin were analysed for Snail expression. MBA-MB-231 breast cancer cells were either mock transfected with vector or with Hugl-2 expression plasmid and selected with G418. E-cadherin promoter was Addgene plasmid #19290. 52 Reporter assays were performed after co-transfection of wild-type or mutated Hugl-2 promoter with pcDNA-Snail-HA or an equal amount of pcDNA empty vector. Luciferase activity was assayed using luciferase assay system (Promega, Mannheim, Germany). All assays were performed in triplicate, repeated at least three times and normalized either using Renilla luciferase activity (Promega) or the protein content of the sample. For apoptosis induction, cells seeded in 96-well plates were treated with 300 ng/ml anti-CD95 antibody. Cell viability was determined by the CellTiter-Glo viability assay kit (Promega) and measured in a Saffire-ELISA reader (Tecan, Salzburg, Austria).
Western blotting and immunofluorescence
Western blots were performed as described using antibodies to HA (Covance, Munich, Germany), anti-Snail (Cell Signalling, Frankfurt, Germany), anti-Hugl-2 polyclonal raised against C-terminal peptide and affinity purified, (Supplementary Figure S2) , anti-E-cadherin, and anti-CK18 (Chemicon International, Hofheim, Germany), anti-Vimentin (GE Healthcare, Freiburg, Germany), Histone 3 (Cell Signalling), b-tubulin (Sigma, Hamburg, Germany), CD31 (Becton Dickinson, Heidelberg, Germany) antiActin (Neomarker, Dreieich, Germany). NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce, Bonn, Germany) was used for subcellular fractionantion. ALP conjugated secondary antibody (Sigma) was used and blots were visualized using Nitroblock-CDP star system (Tropix, Bedford, MA, USA). For immunofluorescence cells were plated in chamber slides and induced with 5 mM of ponasternone A for 24 h before fixation wherever mentioned. Equal amount of ethanol was used to treat control cells. Cells were fixed with 4% PFA and stained with antibodies mentioned above. For nuclear staining of Snail, cells were further treated with 0.1% SDS for permeabilization. AlexaFlour-488 conjugated or Alexa-Flour-546 conjugated secondary antibodies (Molecular Probes, Darmstadt, Germany) were used for visualization.
Hoechst (Molecular Probes) was used for nuclear staining. A confocal laser-scanning microscope (Zeiss cLSM-510UV, Carl Zeiss MicroImaging GmbH) was used for image collection. For comparative fluorescence studies imaging parameters were held constant and quantified using MetaMorph image analysis software, Molecular Devices, Biberach, Germany.
Migration and invasion assays
Either stable transfected cell lines of mock or Snail cells (5 Â 10 6 ) were labelled with 1 mM of cell tracker green or 5 mM of cell tracker red (Molecular Probes). An equal volume of cells were mixed together and plated confluently on 24-well plates. On the cell monolayer a scratch was made and LSM images were acquired immediately and after 24 h. For scratch assay an artificial wound was made in the confluent monolayer of cells by dragging a pipette tip across the well. LSM images at the wound were made at 0 and 24 h from at least 10 different fields. Distance measurements across the wound were made from three different regions in each field. For migration assay using Boyden chamber (BD Bioscience, Heidelberg, Germany) cells were labelled with 1 mM of cell tracker green and 3 Â 10 4 cells were plated in serum-free media. The cells were allowed to migrate in transwell 24-well plates containing FCS and fibronectin. Fluorescence of migrated cells were measured at indicated time points. Invasion assay was performed in the similar way except that Boyden chambers were coated with 0.5 mg/ml matrigel before plating the cells.
ChIP and EMSA
ChIP assays were performed using chromatin-immunoprecipitation kit (Upstate cell signalling, Schwalbach, Germany) according to the manufacturer's instructions. Samples were immunoprecipitated with anti-HA antibody, anti-Snail (Abcam, Cambridge, UK) or rabbit IgG (Sigma). PCR was performed using primers specific for the Hugl-2 and E-cadherin as described in Supplementary Table S1 . Double-stranded oligonucleotides used for EMSA as described in Supplementary Table S2 were labelled with biotin using 3
0 -end DNA labelling kit (Pierce) according to manufacturer's instruction. EMSA was performed using lightshift EMSA optimization and control kit (Pierce). Labelled oligonucleotides were incubated with 1 mg of recombinant Snail-MBP or MBP alone. For competition 200-fold molar excess unlabelled wild-type or mutant oligonucleotides were used. Supershift assay was performed from nuclear extracts of Hek293-Snail-HA cells, using 1 mg of anti-HA antibody.
Tumorigenicity assays
All experiments were performed according to the German Animal Protection Law with permission from the responsible local authorities. Ten-weeks-old NOD-SCID mice were used for xenograft studies. In all, 7.5 Â 10 6 of Hek293 and 2 Â 10 6 of MDA-MB-231 cells were injected s.c. in the inguinal region. Before injection Hek293 cells were induced with 5 mM Ponasterone A or treated with an equivalent amount of dimethylsulphoxide for 48 h. During the experimental time course, Ponasterone A or dimethylsulphoxide in olive oil was injected into the tumour every 5 days. Growth of tumour was measured at an interval of 3 days and mice were killed 4-6 weeks post injection. For metastasis studies 1 Â 10 6 of either MDA-MB-231 or MDA-Hugl-2 cells were injected through lateral tail vein. After 6 weeks mice were killed and analysed. Organs were snap frozen in liquid nitrogen and stored at -70 1C until further analysis.
Statistical analysis
All data were compared using the Student's t-test. P values o0.05 were considered as significant. Error bars on all graphs represent s.e. of the mean.
